Institution
University of São Paulo
Education•São Paulo, Brazil•
About: University of São Paulo is a education organization based out in São Paulo, Brazil. It is known for research contribution in the topics: Population & Context (language use). The organization has 136513 authors who have published 272320 publications receiving 5127869 citations. The organization is also known as: USP & Universidade de São Paulo.
Topics: Population, Context (language use), Medicine, Health care, Immune system
Papers published on a yearly basis
Papers
More filters
••
University of Auckland1, Uppsala University2, GlaxoSmithKline3, Stanford University4, University of Paris5, French Institute of Health and Medical Research6, Imperial College London7, University of Parma8, University of Alberta9, University of São Paulo10, Peking University11, National Taiwan University12, Pontifical Catholic University of Chile13, Milpark Hospital14, University of Amsterdam15, University of Ioannina16, Norfolk and Norwich University Hospital17, University of East Anglia18, Duke University19, University of Buenos Aires20, New York University21, Seoul National University22, University of Ulm23, Charles University in Prague24, Population Health Research Institute25, Autonomous University of Madrid26, University of Pennsylvania27, St. John's University28, University of Oslo29, St George's Hospital30, Katholieke Universiteit Leuven31, Mahidol University32, University of the Philippines33, University of Hong Kong34, Henry Ford Health System35, Tallinn University of Technology36, Carol Davila University of Medicine and Pharmacy37, Fudan University38, Harvard University39
TL;DR: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke.
Abstract: Background Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. Methods In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). Results During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). Conclusions In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).
456 citations
••
B. I. Abelev1, Madan M. Aggarwal2, Zubayer Ahammed3, A. V. Alakhverdyants4 +372 more•Institutions (48)
TL;DR: In this article, the authors investigate a three-particle azimuthal correlator which is a P even observable, but directly sensitive to the charge separation effect, and report measurements of charged hadrons near center-of-mass rapidity with this observable in Au+Au and Cu+Cu collisions at s(NN)=200 GeV using the STAR detector.
Abstract: Parity-odd domains, corresponding to nontrivial topological solutions of the QCD vacuum, might be created during relativistic heavy-ion collisions. These domains are predicted to lead to charge separation of quarks along the system's orbital momentum axis. We investigate a three-particle azimuthal correlator which is a P even observable, but directly sensitive to the charge separation effect. We report measurements of charged hadrons near center-of-mass rapidity with this observable in Au+Au and Cu+Cu collisions at s(NN)=200 GeV using the STAR detector. A signal consistent with several expectations from the theory is detected. We discuss possible contributions from other effects that are not related to parity violation.
454 citations
••
TL;DR: It is argued that a unified theory that includes all classes of tradeoffs would provide a better understanding of the mechanisms that drive the evolution of reaction norms.
Abstract: Tradeoffs have played a prominent role in the development of theories describing the evolution of reaction norms Different classes of tradeoffs are known to constrain the evolution of phenotypes, but current theories incorporate only a subset of these tradeoffs Consequently, these theories cannot account for some of the variation in reaction norms that has been observed within and among species Empirical studies of thermal reaction norms for physiological and life historical traits have shown that different proximate mechanisms can produce similar reaction norms As a consequence, certain tradeoffs can be circumvented when the fitness costs imposed by these tradeoffs are severe We argue that a unified theory that includes all classes of tradeoffs would provide a better understanding of the mechanisms that drive the evolution of reaction norms
454 citations
••
TL;DR: A rapid search in PubMed shows that using "flow cytometry immunology" as a search term yields more than 68 000 articles, the first of which is not about lymphocytes as mentioned in this paper.
Abstract: The marriage between immunology and cytometry is one of the most stable and productive in the recent history of science. A rapid search in PubMed shows that, as of July 2017, using “flow cytometry immunology” as a search term yields more than 68 000 articles, the first of which, interestingly, is not about lymphocytes. It might be stated that, after a short engagement, the exchange of the wedding rings between immunology and cytometry officially occurred when the idea to link fluorochromes to monoclonal antibodies came about. After this, recognizing different types of cells became relatively easy and feasible not only by using a simple fluorescence microscope, but also by a complex and sometimes esoteric instrument, the flow cytometer that is able to count hundreds of cells in a single second, and can provide repetitive results in a tireless manner. Given this, the possibility to analyse immune phenotypes in a variety of clinical conditions has changed the use of the flow cytometer, which was incidentally invented in the late 1960s to measure cellular DNA by using intercalating dyes, such as ethidium bromide. The epidemics of HIV/AIDS in the 1980s then gave a dramatic impulse to the technology of counting specific cells, since it became clear that the quantification of the number of peripheral blood CD4+ T cells was crucial to follow the course of the infection, and eventually for monitoring the therapy. As a consequence, the development of flow cytometers that had to be easy-to-use in all clinical laboratories helped to widely disseminate this technology. Nowadays, it is rare to find an immunological paper or read a conference abstract in which the authors did not use flow cytometry as the main tool to dissect the immune system and identify its fine and complex functions. Of note, recent developments have created the sophisticated technology of mass cytometry, which is able to simultaneously identify dozens of molecules at the single cell level and allows us to better understand the complexity and beauty of the immune system.
454 citations
••
University of Cagliari1, University of Sydney2, Katholieke Universiteit Leuven3, Lund University4, University of Milan5, University of Rome Tor Vergata6, University of São Paulo7, Pierre-and-Marie-Curie University8, University of Navarra9, University of Bologna10, Leeds Teaching Hospitals NHS Trust11, Wollongong Hospital12, Imperial College London13, University of Genoa14, University College Hospital15, Brigham and Women's Hospital16, University of Tokyo17
TL;DR: The IDEA (International Deep Endometriosis Analysis group) statement is a consensus opinion on terms, definitions and measurements that may be used to describe the sonographic features of the different phenotypes of endometiosis.
Abstract: The IDEA (International Deep Endometriosis Analysis group) statement is a consensus opinion on terms, definitions and measurements that may be used to describe the sonographic features of the different phenotypes of endometriosis. Currently, it is difficult to compare results between published studies because authors use different terms when describing the same structures and anatomical locations. We hope that the terms and definitions suggested herein will be adopted in centers around the world. This would result in consistent use of nomenclature when describing the ultrasound location and extent of endometriosis. We believe that the standardization of terminology will allow meaningful comparisons between future studies in women with an ultrasound diagnosis of endometriosis and should facilitate multicenter research. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
454 citations
Authors
Showing all 138091 results
Name | H-index | Papers | Citations |
---|---|---|---|
George M. Whitesides | 240 | 1739 | 269833 |
Peter Libby | 211 | 932 | 182724 |
Robert C. Nichol | 187 | 851 | 162994 |
Paul M. Thompson | 183 | 2271 | 146736 |
Terrie E. Moffitt | 182 | 594 | 150609 |
Douglas R. Green | 182 | 661 | 145944 |
Richard B. Lipton | 176 | 2110 | 140776 |
Robin M. Murray | 171 | 1539 | 116362 |
George P. Chrousos | 169 | 1612 | 120752 |
David A. Bennett | 167 | 1142 | 109844 |
Barry M. Popkin | 157 | 751 | 90453 |
David H. Adams | 155 | 1613 | 117783 |
Joao Seixas | 153 | 1538 | 115070 |
Matthias Egger | 152 | 901 | 184176 |
Ichiro Kawachi | 149 | 1216 | 90282 |